The purpose of the study is to see if a new investigational drug called bempedoic acid reduces the risk of major cardiovascular (heart and blood vessel-related) events in patients with, or at high risk for, heart disease who have had complications related to taking statins. The study will compare bempedoic acid with a placebo to see if taking bempedoic acid is better than taking a placebo.
Research study looking for participants with, or at high risk for, cardiovascular disease (CVD). This study is being carried out to see if a new investigational drug called bempedoic acid provides cardiovascular benefits and decreases the risks of future cardiac events when taken by patients who are not able to take a type of medication called statins. The study may require up to 15 visits to the clinic over a period of five years.
The CASCADE FH Registry is a national, multi?center initiative that will track the therapy, clinical outcomes, and patient?reported outcomes over time. The Registry represents collaboration between The FH Foundation, lipid specialists, cardiologists, primary care providers, quality improvement personnel, and patients, all aiming to increase FH awareness, promote optimal disease management, and improve FH outcomes. The Duke Clinical Research Institute will help operationalize the clinical portal of the CASCADE FH Registry. The Registry will use a hybrid enrollment design to maximize outreach and ensure that all interested FH patients have the option to participate. In accordance with these goals, participants will be identified using a variety of mechanisms, including screening by providers and online screening tools available to the general public. MUSC will only follow the clinical, prospective data collection method outlined in the protocol for this study. Cross?validation of clinical data with patient?entered data will optimize quality and promote statistical validity.
This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide. The purpose is to evaluate the occurrence of adverse events of special interest, long term effectiveness of Lomitapide, and to evaluate whether prescribers of Lomitapide are following screening and monitoring recommendations as specified in product labeling.